Chinese herbal medicine Ginkgo biloba L. preparations for ischemic stroke: An overview of systematic reviews and meta-analyses.

Stroke is one of the leading causes of disability worldwide, and researchers are constantly looking for ways to improve recovery outcomes. A recent scientific review published in the Journal of Integrative Medicine explored whether preparations made from Ginkgo biloba — a plant long used in Chinese herbal medicine — could help people recovering from ischemic stroke, the most common type caused by a blocked blood vessel in the brain.

The researchers didn't conduct a new clinical trial. Instead, they reviewed 29 previously published systematic reviews and meta-analyses, which are studies that pool results from many individual trials to find patterns. In total, these reviews covered 119 different health outcomes in stroke patients.

The findings were cautiously encouraging. When Ginkgo biloba preparations were used alongside conventional medical treatment, patients showed better neurological function scores compared to those receiving conventional treatment alone. This suggests the herbal preparations may offer meaningful support as an add-on therapy during stroke recovery.

However, there's an important catch: the overall quality of the research was rated as low to very low. Most of the underlying studies had significant weaknesses in how they were designed and reported, making it difficult to draw firm conclusions. The authors stress that better-designed clinical trials are urgently needed before Ginkgo biloba preparations can be confidently recommended as a standard part of stroke care.

For patients, this means Ginkgo biloba shows real promise as a complementary therapy, but it should only be used under proper medical supervision and never as a replacement for prescribed stroke treatments. If you're interested in exploring Chinese herbal medicine as part of your recovery plan, speak with a licensed practitioner who is trained in both Traditional Chinese Medicine and is aware of your full medical history.

This overview assessed 29 systematic reviews and meta-analyses (SRs/MAs) evaluating Ginkgo biloba L. preparations (GBLPs) as adjuvant therapy for ischemic stroke (IS), covering 119 outcomes from RCT-based evidence pools. Methodological quality was assessed using AMSTAR 2, ROBIS, PRISMA, and GRADE frameworks. Results were markedly limited: all 29 SRs/MAs rated critically low on AMSTAR 2, 28 demonstrated high risk of bias per ROBIS, and GRADE evidence quality was very low for 87 outcomes, low for 24, and moderate for only 8. Despite these limitations, data synthesis consistently showed GBLPs combined with conventional treatment outperformed conventional treatment alone in reducing neurological function deficit scores. No significant safety signals were highlighted. Clinical takeaway: GBLPs may offer adjunctive benefit in IS rehabilitation, particularly for neurological recovery endpoints, but the evidence base is currently insufficient to support formal clinical integration. High-quality, well-reported RCTs are required to establish reliable efficacy and safety profiles.